Age-related differences in the immune response could contribute to determine the spectrum of severity of COVID-19.
Adaptive Immunity
Adolescent
Adult
Age Factors
Age of Onset
Aged
Aging
/ immunology
Angiotensin-Converting Enzyme 2
/ biosynthesis
COVID-19
/ etiology
Child
Child, Preschool
Comorbidity
Cytokine Release Syndrome
/ etiology
Humans
Immunity, Innate
Infant
Inflammation
/ immunology
Lymphocyte Subsets
/ immunology
Male
Middle Aged
Receptors, Virus
/ biosynthesis
SARS-CoV-2
Severity of Illness Index
Systemic Inflammatory Response Syndrome
/ etiology
Young Adult
ACE2
children
coronavirus
cytokine storm
immune dysregulation
multisystem inflammatory syndrome in children (MIS-C)
Journal
Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
24
11
2020
received:
23
10
2020
accepted:
28
12
2020
pubmed:
11
2
2021
medline:
22
5
2021
entrez:
10
2
2021
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19), can present with a wide spectrum of severity. Elderly patients with cardiac, pulmonary and metabolic comorbidities are more likely to develop the severe manifestations of COVID-19, which are observed in less than 5% of the pediatric patients. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is able to induce an immune impairment and dysregulation, finally resulting in the massive release of inflammatory mediators, strongly contributing to the pulmonary and systemic manifestations in COVID-19. In children, the immune dysregulation following SARS-CoV-2 can also be responsible of a severe disease phenotype defined as multisystem inflammatory syndrome in children. As the immune system undergoes a complex process of maturation from birth to adult age, differences in the immune and inflammatory response could have a significant impact in determining the spectrum of severity of COVID-19. Indeed, children show a higher ability to respond to viral infections and a reduced baseline pro-inflammatory state compared with elderly patients. Age and comorbidities contribute to disease severity through immune-mediated mechanisms, since they are associated with a chronic increase of pro-inflammatory mediators, and cause an enhanced susceptibility to develop an immune dysregulation following SARS-CoV-2 infection. Also the expression of ACE2, the receptor of SARS-CoV-2, varies with age, and is linked to the immune and inflammatory response through a complex, and not completely elucidated, network. This paper reviews the peculiar immunopathogenic aspects of COVID-19, with a focus on the differences between adult and pediatric patients.
Identifiants
pubmed: 33566457
doi: 10.1002/iid3.404
pmc: PMC8014746
doi:
Substances chimiques
Receptors, Virus
0
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Comparative Study
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
331-339Informations de copyright
© 2021 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
Références
N Engl J Med. 2020 Jul 23;383(4):334-346
pubmed: 32598831
Life Sci. 2006 Apr 4;78(19):2166-71
pubmed: 16303146
N Engl J Med. 2020 Sep 10;383(11):1078-1080
pubmed: 32905684
Cell Host Microbe. 2020 Jun 10;27(6):870-878
pubmed: 32464097
Eur Respir J. 2020 May 14;55(5):
pubmed: 32269089
Pediatr Infect Dis J. 2020 Jun;39(6):469-477
pubmed: 32398569
J Immunol. 1993 Jan 15;150(2):543-9
pubmed: 8419487
Immun Inflamm Dis. 2021 Jun;9(2):331-339
pubmed: 33566457
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
J Virol. 2010 Sep;84(18):9318-25
pubmed: 20610717
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Eur J Pediatr. 2020 Jul;179(7):1029-1046
pubmed: 32424745
J Med Virol. 2020 Jul;92(7):747-754
pubmed: 32232980
Int J Infect Dis. 2020 Jul;96:710-714
pubmed: 32389849
J Virol. 2007 Aug;81(16):8692-706
pubmed: 17537853
Elife. 2020 Nov 09;9:
pubmed: 33164753
Eur Respir J. 2020 Aug 20;56(2):
pubmed: 32675207
Int J Antimicrob Agents. 2020 May;55(5):105954
pubmed: 32234467
Immun Ageing. 2009 Jul 22;6:10
pubmed: 19624841
J Infect. 2020 Aug;81(2):e16-e25
pubmed: 32335169
Inflamm Res. 2020 Sep;69(9):825-839
pubmed: 32529477
Nat Rev Immunol. 2020 Aug;20(8):453-454
pubmed: 32546853
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Eur J Pediatr. 2020 Aug;179(8):1315-1323
pubmed: 32495147
MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):422-426
pubmed: 32271728
Curr Treatm Opt Rheumatol. 2017 Mar;3(1):33-48
pubmed: 28944163
Nat Rev Immunol. 2014 Jan;14(1):24-35
pubmed: 24336101
Virus Genes. 2011 Feb;42(1):37-45
pubmed: 20976535
Lancet. 2020 May 23;395(10237):1607-1608
pubmed: 32386565
Cell. 2020 May 28;181(5):1016-1035.e19
pubmed: 32413319
Pharmacol Res. 2020 Jul;157:104833
pubmed: 32302706
Travel Med Infect Dis. 2020 Mar - Apr;34:101623
pubmed: 32179124
J Korean Med Sci. 2016 Nov;31(11):1717-1725
pubmed: 27709848
Proc Nutr Soc. 2012 May;71(2):332-8
pubmed: 22429824
J Exp Med. 2015 Oct 19;212(11):1851-68
pubmed: 26392224
Cell. 2020 Nov 12;183(4):968-981.e7
pubmed: 32966765
N Engl J Med. 2020 Apr 23;382(17):1663-1665
pubmed: 32187458
Nat Rev Rheumatol. 2016 May;12(5):259-68
pubmed: 27009539
Trends Immunol. 2009 Jul;30(7):306-12
pubmed: 19540809
Front Immunol. 2019 Feb 27;10:318
pubmed: 30873171
World J Pediatr. 2020 Jun;16(3):251-259
pubmed: 32193831
Transpl Int. 2020 Jul;33(7):824-825
pubmed: 32236983
Cell Physiol Biochem. 2015;37(2):759-67
pubmed: 26356266
Int J Mol Sci. 2020 Aug 12;21(16):
pubmed: 32806722
Pediatr Res. 2021 Mar;89(4):733-737
pubmed: 32555539
Allergy. 2020 Nov;75(11):2829-2845
pubmed: 32496587
Arthritis Rheum. 2012 May;64(5):1680-8
pubmed: 22108837
Ann Rheum Dis. 2016 Mar;75(3):481-9
pubmed: 26865703
Pediatr Pulmonol. 2020 Aug;55(8):1892-1899
pubmed: 32492251
Sci Rep. 2016 Jan 27;6:19840
pubmed: 26813885
Vaccine. 2018 Sep 18;36(39):5811-5818
pubmed: 30143274
Lancet. 2020 Jun 6;395(10239):1771-1778
pubmed: 32410760
Best Pract Res Clin Rheumatol. 2014 Apr;28(2):277-92
pubmed: 24974063
Autoimmun Rev. 2020 Jun;19(6):102537
pubmed: 32251717
Int Immunol. 2012 Jun;24(6):347-56
pubmed: 22345276
Nat Rev Immunol. 2014 Jan;14(1):36-49
pubmed: 24362405
Proc Am Thorac Soc. 2009 Dec 1;6(7):573-80
pubmed: 19934352
Environ Toxicol Pharmacol. 2020 Aug;78:103411
pubmed: 32422280
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Trends Immunol. 2009 Jul;30(7):313-8
pubmed: 19540810
Cell Mol Immunol. 2020 May;17(5):541-543
pubmed: 32203186
Geroscience. 2020 Apr;42(2):505-514
pubmed: 32274617
Immun Ageing. 2019 Sep 11;16:24
pubmed: 31528179
J Autoimmun. 2020 Aug;112:102463
pubmed: 32303424
J Med Virol. 2021 Jan;93(1):257-261
pubmed: 32603481
J Med Virol. 2020 Apr;92(4):424-432
pubmed: 31981224
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Eur Cytokine Netw. 2018 Sep 1;29(3):83-94
pubmed: 30547890
Mech Ageing Dev. 2006 Mar;127(3):274-81
pubmed: 16352331
Front Oncol. 2020 Jan 31;9:1529
pubmed: 32076597
Cell Stem Cell. 2020 May 7;26(5):657-674.e8
pubmed: 32169166
Clin Exp Rheumatol. 2020 Mar-Apr;38(2):337-342
pubmed: 32202240
Children (Basel). 2020 Jul 01;7(7):
pubmed: 32630212
J Pathol. 2006 Nov;210(3):288-97
pubmed: 17031779